Qian Guo

Qian Guo

Auto-generated profile, based on publicly available information

Qian Guo

Peking University Cancer Hospital 1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Communications Medicine
Verified
Journal Article
Open access
PDF file
XXXu Xiao
Xu Xiao
QGQian Guo
Qian Guo
CCChuanliang Cui
Chuanliang Cui
YLYating Lin
Yating Lin
LZLei Zhang
Lei Zhang
RYRongshan Yu
Rongshan Yu
Background: Single-cell technologies have enabled extensive analysis of complex immune composition, phenotype and interactions within tumor, which is crucial in understanding the mechanisms behind cancer progression and treatment resistance. Unfortunately, knowledge on cell phenotypes and their spatial interactions has only had limited impact on the pathological stratification of patients in the clinic so far. We explore the relationship between different tumor environments (TMEs) and response to immunotherapy by deciphering the composition and spatial relationships of different cell types. Methods: Here we used imaging mass cytometry to simultaneously quantify 35 proteins in a spatially resolved manner on tumor tissues from 26 melanoma patients receiving anti-programmed cell death-1 (anti-PD-1) therapy. Using unsupervised clustering, we profiled 662,266 single cells to identify lymphocytes, myeloid derived monocytes, stromal and tumor cells, and characterized TME of different melanomas. Results: Combined single-cell and spatial analysis reveals highly dynamic TMEs that are characterized with variable tumor and immune cell phenotypes and their spatial organizations in melanomas, and many of these multicellular features are associated with response to anti-PD-1 therapy. We further identify six distinct TME archetypes based on their multicellular compositions, and find that patients with different TME archetypes responded differently to anti-PD-1 therapy. Finally, we find that classifying patients based on the gene expression signature derived from TME archetypes predicts anti-PD-1 therapy response across multiple validation cohorts. Conclusions: Our results demonstrate the utility of multiplex proteomic imaging technologies in studying complex molecular events in a spatially resolved manner for the development of new strategies for patient stratification and treatment outcome prediction.

5 September 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
JSJing Shi
Jing Shi
TJTao Jiao
Tao Jiao
QGQian Guo
Qian Guo
WWWeining Weng
Weining Weng
LMLinjie Ma
Linjie Ma
XMXun Meng
Xun Meng
Recent advances in targeted therapy and immunotherapy have substantially improved the treatment of melanoma. However, therapeutic strategies are still needed for unresponsive or treatment-relapsed patients with melanoma. To discover antibody–drug conjugate (ADC)–tractable cell surface targets for melanoma, we developed an atlas of melanoma cell surface–binding antibodies (pAb) using a proteome-scale antibody array platform. Target identification of pAbs led to development of melanoma cell killing ADCs against LGR6, TRPM1, ASAP1, and MUC18, among others. MUC18 was overexpressed in both tumor cells and tumor-infiltrating blood vessels across major melanoma subtypes, making it a potential dual-compartment and universal melanoma therapeutic target. AMT-253, an MUC18-directed ADC based on topoisomerase I inhibitor exatecan and a self-immolative T moiety, had a higher therapeutic index compared with its microtubule inhibitor–based counterpart and favorable pharmacokinetics and tolerability in monkeys. AMT-253 exhibited MUC18-specific cytotoxicity through DNA damage and apoptosis and a strong bystander killing effect, leading to potent antitumor activities against melanoma cell line and patient-derived xenograft models. Tumor vasculature targeting by a mouse MUC18-specific antibody–T1000-exatecan conjugate inhibited tumor growth in human melanoma xenografts. Combination therapy of AMT-253 with an antiangiogenic agent generated higher efficacy than single agent in a mucosal melanoma model. Beyond melanoma, AMT-253 was also efficacious in a wide range of MUC18-expressing solid tumors. Efficient target/antibody discovery in combination with the T moiety–exatecan linker–payload exemplified here may facilitate discovery of new ADC to improve cancer treatment. Significance: Discovery of melanoma-targeting antibodies using a proteome-scale array and use of a cutting-edge linker–payload system led to development of a MUC18-targeting antibody–exatecan conjugate with clinical potential for treating major melanoma subtypes.

21 December 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WTWei Tian
Wei Tian
QGQian Guo
Qian Guo
DFDaidi Fu
Daidi Fu
XMXiao Ma
Xiao Ma
RWRui Wang
Rui Wang
Objectives: Several prospective trials had been reported on chemotherapy with or without antiangiogenic agents in patients with advanced malignant pleural mesothelioma (MPM), with diverse results. We performed this systematic review and meta-analysis to evaluate the efficacy and safety of the combination regimen. Methods: We systematically identified trials in several databases, including MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, ASCO Abstracts and ESMO Abstracts. All the randomized controlled trials (RCTs) about chemotherapy combined with antiangiogenic agents in advanced MPM were identified. Overall survival (OS) was the primary outcome, while progression-free survival (PFS), overall response rate (ORR) and serious toxicities were the secondary outcomes. Review Manager 5.3 was used to perform the statistical analyses. Stata 12.0 was used to assess the publication bias of egger’s test. Results: 5 randomized controlled trials containing 1250 patients were finally included in this analysis. Statistical analyses showed that the addition of antiangiogenic agents to chemotherapy could prolong OS [HR 0.79 (0.71–0.89), p<0.0001] and PFS [HR 0.75 (0.68–0.84), p<0.00001] in advanced MPM, especially in the epithelioid subgroup, with a tolerable toxicity profile. No significant difference was found in the analysis of ORR [HR 1.13 (0.95–1.35), p = 0.18]. Heterogeneity was found in the analyses of PFS and ORR, which might be caused by the limitation in uniform evaluation of tumor response. Conclusions: The combination of antiangiogenic agents with chemotherapy showed superior over chemotherapy alone in patients with advanced MPM. More prospective trials should be warranted to identify patients who would most likely benefit from the combination regimen.

15 November 2023
Verified
Other
Open access
JSJing Shi
Jing Shi
TJTao Jiao
Tao Jiao
QGQian Guo
Qian Guo
WWWeining Weng
Weining Weng
LMLinjie Ma
Linjie Ma
XMXun Meng
Xun Meng
Recent advances in targeted therapy and immunotherapy have substantially improved the treatment of melanoma. However, therapeutic strategies are still needed for unresponsive or treatment-relapsed patients with melanoma. To discover antibody–drug conjugate (ADC)–tractable cell surface targets for melanoma, we developed an atlas of melanoma cell surface–binding antibodies (pAb) using a proteome-scale antibody array platform. Target identification of pAbs led to development of melanoma cell killing ADCs against LGR6, TRPM1, ASAP1, and MUC18, among others. MUC18 was overexpressed in both tumor cells and tumor-infiltrating blood vessels across major melanoma subtypes, making it a potential dual-compartment and universal melanoma therapeutic target. AMT-253, an MUC18-directed ADC based on topoisomerase I inhibitor exatecan and a self-immolative T moiety, had a higher therapeutic index compared with its microtubule inhibitor–based counterpart and favorable pharmacokinetics and tolerability in monkeys. AMT-253 exhibited MUC18-specific cytotoxicity through DNA damage and apoptosis and a strong bystander killing effect, leading to potent antitumor activities against melanoma cell line and patient-derived xenograft models. Tumor vasculature targeting by a mouse MUC18-specific antibody–T1000-exatecan conjugate inhibited tumor growth in human melanoma xenografts. Combination therapy of AMT-253 with an antiangiogenic agent generated higher efficacy than single agent in a mucosal melanoma model. Beyond melanoma, AMT-253 was also efficacious in a wide range of MUC18-expressing solid tumors. Efficient target/antibody discovery in combination with the T moiety–exatecan linker–payload exemplified here may facilitate discovery of new ADC to improve cancer treatment.Significance:Discovery of melanoma-targeting antibodies using a proteome-scale array and use of a cutting-edge linker–payload system led to development of a MUC18-targeting antibody–exatecan conjugate with clinical potential for treating major melanoma subtypes.

9 November 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
LZLi Zhou
Li Zhou
XCXiaojun Cai
Xiaojun Cai
HDHaizhen Du
Haizhen Du
XWXuan Wang
Xuan Wang
YYYue Yang
Yue Yang
CCChuanliang Cui
Chuanliang Cui
More than 70% of melanomas in China are acral or mucosal subtypes, which respond poorly to immune checkpoint inhibitors (ICI). Tumor-infiltrating lymphocyte (TIL) therapy is active in metastatic melanoma, with evidence from cutaneous-predominant cohorts and immune correlates undefined in Asian patients. We evaluated an autologous TIL therapy LM103 in Chinese patients with refractory metastatic melanoma. Fourteen patients received lymphodepleting chemotherapy followed by LM103 infusion (3.58–19.47 × 1010 cells) and high-dose interleukin 2 (IL2). Characteristics of baseline tumor, TIL products, and pre-/postinfusion peripheral blood were analyzed. All patients experienced myelosuppression and capillary leak syndrome. Grade 3 to 4 treatment-emergent adverse events (TEAE) included leukopenia (85.7%), neutropenia (78.6%), lymphopenia (78.6%), fever (71.4%), and thrombocytopenia (57.1%). The objective response rate (ORR) was 35.7% [95% confidence interval (CI), 12.76–64.86], and the disease control rate (DCR) was 85.7% (95% CI, 57.19–98.22). The median progression-free survival (PFS) was 4.52 months (95% CI, 2.07–14.31), and the median overall survival (OS) was 16.58 months (95% CI, 5.16–not estimable). Baseline tumor immune infiltration and tumor mutational burden (TMB) were not associated with clinical outcome. LM103 induced marked peripheral T-cell receptor (TCR) repertoire remodeling, with >60% of infused TIL clones detectable at 6 months. Patients with superior outcomes demonstrated greater expansion and persistence of dominant TIL clones. Genes favoring T-cell tumor infiltration were upregulated in TILs of patients with longer PFS. LM103 showed manageable safety and encouraging antitumor activity. Clinical benefit was associated with sustained in vivo clonal persistence and upregulated genes favoring tumor re-infiltration of infused TILs. The trial registration number is CTR20233999. Significance: In a phase I trial, clinical benefit of autologous TIL therapy with LM103 is associated with sustained in vivo clonal persistence and upregulation of genes favoring tumor re-infiltration of infused TILs.

15 November 2023
Verified
Other
Open access
JSJing Shi
Jing Shi
TJTao Jiao
Tao Jiao
QGQian Guo
Qian Guo
WWWeining Weng
Weining Weng
LMLinjie Ma
Linjie Ma
XMXun Meng
Xun Meng
Recent advances in targeted therapy and immunotherapy have substantially improved the treatment of melanoma. However, therapeutic strategies are still needed for unresponsive or treatment-relapsed patients with melanoma. To discover antibody–drug conjugate (ADC)–tractable cell surface targets for melanoma, we developed an atlas of melanoma cell surface–binding antibodies (pAb) using a proteome-scale antibody array platform. Target identification of pAbs led to development of melanoma cell killing ADCs against LGR6, TRPM1, ASAP1, and MUC18, among others. MUC18 was overexpressed in both tumor cells and tumor-infiltrating blood vessels across major melanoma subtypes, making it a potential dual-compartment and universal melanoma therapeutic target. AMT-253, an MUC18-directed ADC based on topoisomerase I inhibitor exatecan and a self-immolative T moiety, had a higher therapeutic index compared with its microtubule inhibitor–based counterpart and favorable pharmacokinetics and tolerability in monkeys. AMT-253 exhibited MUC18-specific cytotoxicity through DNA damage and apoptosis and a strong bystander killing effect, leading to potent antitumor activities against melanoma cell line and patient-derived xenograft models. Tumor vasculature targeting by a mouse MUC18-specific antibody–T1000-exatecan conjugate inhibited tumor growth in human melanoma xenografts. Combination therapy of AMT-253 with an antiangiogenic agent generated higher efficacy than single agent in a mucosal melanoma model. Beyond melanoma, AMT-253 was also efficacious in a wide range of MUC18-expressing solid tumors. Efficient target/antibody discovery in combination with the T moiety–exatecan linker–payload exemplified here may facilitate discovery of new ADC to improve cancer treatment.Significance:Discovery of melanoma-targeting antibodies using a proteome-scale array and use of a cutting-edge linker–payload system led to development of a MUC18-targeting antibody–exatecan conjugate with clinical potential for treating major melanoma subtypes.